Chemotheraphy Induced Nausea and Vomitting Drugs Market

Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of many cancer treatments. Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families. In 1983, Coates et al. found that patients receiving chemotherapy ranked nausea and vomiting as the first and second most severe side effects, respectively. Up to 20% of patients receiving highly emetogenic agents in this era postponed, or even refused, potentially curative treatments. Since the 1990s, several novel classes of antiemetics have been developed and commercialized, becoming a nearly universal standard in chemotherapy regimens, and helping to better manage these symptoms in a large portion of patients. Efficient mediation of these unpleasant and sometimes crippling symptoms results in increased quality of life for the patient, and better overall health of the patient, and, due to better patient tolerance, more effective treatment cycles.

Affecting 70-80% of patients undergoing chemotherapy, chemotherapy-induced nausea and vomiting (CINV) is one of chemotherapy's most debilitating side effects, often attributed as a leading cause of premature discontinuation of cancer treatment.

Chemotheraphy Induced Nausea and Vomitting Drugs Market contains market size and forecasts of Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs in global, including the following market information:

Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Sales, 2017-2022, 2023-2028, (M Units)

Global top five Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs companies in 2021 (%)

The global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs market was valued at 2431.4 million in 2021 and is projected to reach US$ 2182.5 million by 2028, at a CAGR of -1.5% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

5-HT3 Inhibitors Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs include Heron Therapeutics, Merck, Eisai, Mundipharma, Qilu Pharma, Teva, Novartis, Roche and Mylan, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (M Units)

Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Segment Percentages, by Type, 2021 (%)

• 5-HT3 Inhibitors
• NK1 Inhibitors
• Others

Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (M Units)

Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Segment Percentages, by Application, 2021 (%)

• Acute CINV
• Delayed CINV
• Breakthrough CINV
• Others

Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (M Units)

Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
• Key companies Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs revenues share in global market, 2021 (%)
• Key companies Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs sales in global market, 2017-2022 (Estimated), (M Units)
• Key companies Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Heron Therapeutics
• Merck
• Eisai
• Mundipharma
• Qilu Pharma
• Teva
• Novartis
• Roche
• Mylan
• Baxter
• GSK
• Helsinn
• Southwest Pharma
• Haisco
• Sun Pharma